A Bivalent Omicron-Containing Booster Vaccine against Covid-19.

ABSTRACT:

Background

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.

Methods

In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-μg) primary series and first booster (50-μg) dose of mRNA-1273 (≥3 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose.

Results

Interim results are presented. Sequential groups of participants received

SUBMITTER: Chalkias S 

PROVIDER: S-EPMC9511634 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature